Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial

BACKGROUND: This analysis aimed at evaluating the impact of a therapeutic strategy of treatment simplification of atazanavir (ATV)+ ritonavir (r) + lamivudine (3TC) in virologically suppressed patients receiving ATV+r+2 nucleoside reverse transcriptase inhibitors (NRTIs) on the budget of the Italian...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clinicoecon Outcomes Res
Autors principals: Restelli, Umberto, Fabbiani, Massimiliano, Di Giambenedetto, Simona, Nappi, Carmela, Croce, Davide
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2017
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5338853/
https://ncbi.nlm.nih.gov/pubmed/28280375
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S127097
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars